세포 치료 및 유전자 치료 시장 규모, 점유율, 성장 분석 : 치료법별, 치료 분야별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Cell & Gene Therapy Market size was valued at USD 29.44 Billion in 2024 and is poised to grow from USD 34.88 Billion in 2025 to USD 135.62 Billion by 2033, growing at a CAGR of 18.5% during the forecast period (2026-2033).

The global cell and gene therapy market is significantly propelled by the rising prevalence of chronic diseases, including cancer and rare genetic disorders, which often elude effective treatment from traditional modalities. This ongoing medical challenge drives healthcare professionals and pharmaceutical entities to pursue innovative therapies that provide targeted and personalized solutions. The growing pool of diagnosed patients, aided by advancements in screening and an aging demographic, further fuels demand for these therapies, resulting in increased investment and clinical trials. Breakthroughs in biotechnology, particularly with gene editing technologies like CRISPR-Cas9, enhance therapeutic precision and patient safety, facilitating regulatory approvals. These advancements not only accelerate research and development but also attract further investments, broadening the array of novel treatments in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell & Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell & Gene Therapy Market Segments Analysis

The global cell and gene therapy market is segmented based on therapy type, therapeutic class, end-users, and region. In terms of therapy type, the market is bifurcated into cell therapy and gene therapy. Based on therapeutic class, the market is segmented into cardiovascular disease, cancer, genetic disorder, rare diseases, oncology, hematology, ophthalmology, infectious disease, neurological disorders, and others. Based on end-users, the market is trifurcated into hospitals, cancer care centers, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Central & South America and the Middle East & Africa.

Driver of the Global Cell & Gene Therapy Market

The increasing prevalence of genetic disorders and rare diseases significantly propels the cell and gene therapy market. These advanced therapies provide curative solutions for ailments once thought to be untreatable, attracting considerable interest from both patients and healthcare providers. With heightened patient demand and advancements in diagnostic technologies, there is an escalating necessity for innovative and targeted treatment options. This trend fosters a robust environment for the global cell and gene therapy market, encouraging further development and investment in groundbreaking therapies aimed at tackling complex health challenges. As a result, the market is experiencing substantial growth and expansion opportunities.

Restraints in the Global Cell & Gene Therapy Market

The Global Cell and Gene Therapy market faces significant constraints due to the extensive preclinical research, intricate clinical trials, and stringent regulatory approval processes required for developing these therapies. The lengthy timeline for bringing products to market not only delays their availability but also escalates research and development costs. This challenge is particularly pronounced for smaller companies, which often find it difficult to manage prolonged investment cycles. As a result, innovation may be hindered, ultimately affecting the rate of new therapies entering the global market and limiting advancements in treatment options for patients.

Market Trends of the Global Cell & Gene Therapy Market

The global cell and gene therapy market is witnessing a transformative trend driven by the emergence of personalized medicine, which tailors treatments to the unique genetic profiles of patients. This individualized approach enhances therapeutic efficacy and minimizes adverse side effects, making it particularly beneficial for addressing rare and complex diseases. As healthcare becomes increasingly focused on patient-centric solutions, the demand for innovative therapies that harness genetic insights is surging. This trend not only accelerates market growth but also fosters a collaborative environment among researchers, healthcare providers, and biotechnology firms, ultimately leading to more effective treatments and better patient outcomes on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Cell and Gene Therapy Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Cell Therapy
• Gene Therapy

Global Cell and Gene Therapy Market Size by Modality & CAGR (2026-2033)

• Market Overview
• In Vivo
• Ex Vivo

Global Cell and Gene Therapy Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Musculoskeletal Disorders
• Ophthalmic Disorders
• Metabolic & Genetic Disorders
• Infectious Diseases
• Others

Global Cell and Gene Therapy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Academic & Research Institutes
• Biopharmaceutical & Biotechnology Companies
• Cell Therapy Centers
• Others

Global Cell and Gene Therapy Market Size & CAGR (2026-2033)

• North America (Therapy Type, Modality, Indication, End User)
  • US
  • Canada
• Europe (Therapy Type, Modality, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Modality, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Modality, Indication, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Modality, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UniQure (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regenxbio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spark Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fosun Pharma (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations